Brepocitinib

N/A

Report date: 2026/05/28 20:00:21
NME

Base Information

Drug NameBrepocitinib
Drug Alias NameBrepocitinib tosylatePF-06700841PF-06700841-15PF-6700841PF-841
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase 2 inhibitorsTyrosine-protein kinase JAK1 inhibitors
TargetsTyrosine-protein kinase 2Tyrosine-protein kinase JAK1
Therapy Area/IndicationsPlaque psoriasisPsoriasisLichen Planus +[19] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[46] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPriovant Therapeutics IncPfizer LtdPfizer Inc +[4] 
Inactive CompaniesN/A
Active IndicationsPsoriasisLichen PlanusVitiligo +[16] 
Inactive IndicationsPlaque psoriasisAlopecia AreataArthritis, Psoriatic

Other Information

ATC CodeN/A
Related LinksN/A